Patterns of hematologic adverse events grade 3 or higher
lymphopenia, HAE, hematotoxicity, neutropenia
ADVERSE EVENTS, NEUTROPENIA, LYMPHOPENIA
The prevalence of HAE was higher in patients treated with CCNU/TMZ compared to treatment with TMZ alone without reaching statistical significance (36.4% (24 of 66) vs. 28.6% (18 of 63), respectively, p = 0.36) as reported before [
 Swimmer plot with individual patient data on applied chemotherapy courses and hematotoxicity. Crosses indicate hematological adverse events CTCAE grade 3 or 4, triangles indicate discontinuation of chemotherapy due to hematotoxicity or a resulting delay of more than 6 weeks. The duration of HAE in the concomitant phase of chemotherapy was longer in the TMZ arm (concomitant: median 20 days, IQR 13–36.5, n = 13) compared to the CCNU/TMZ arm (1st course: median 10 days, IQR 2–24, n = 15) without reaching statistical significance (p = 0.10). We observed the opposite for HAE during adjuvant courses; the median duration in TMZ was 6.5 days (IQR 4.5–13.25), compared to CCNU/TMZ with 20 days (IQR 11.25–51.5, p = 0.004). For all HAE episodes combined, the median duration was 11.5 days (IQR 5.25–22.75) in the CCNU/TMZ arm and 13 days (IQR 6.75–23.25) in the TMZ arm, respectively (p = 0.46). The duration of lymphopenia grade 3 or 4 was longer under CCNU/TMZ treatment, but this observation was based on a low number of cases (Table 
Median duration and interquartile range (IQR) of hematotoxicity grade 3 or 4 episodesHigh risk neutropenia, defined as CTCAE grade 4 neutropenia > 7 days [